Active, Not Recruiting

  1. BI 1839100 Study
    A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough.
    Trial Age Group: Over 18 years Over 40 years Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Progressive Pulmonary Fibrosis Trial Participant Type: Carer Trial Phase: Phase 2 Trial Location: ACT New Zealand NSW TAS VIC WA Trial Status: Active, not recruiting Trial Type: Interventional
  2. BEACON-IPF
    A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF).
    Trial Age Group: Over 40 years Trial Disease Type: Idiopathic Pulmonary Fibrosis (IPF) Trial Participant Type: Patient Trial Phase: Phase 2 Trial Location: New Zealand NSW QLD SA VIC WA Trial Status: Active, not recruiting Trial Type: Interventional